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Table 3
Correlation between involvement of different parts of gastrointestinal tract
e colon/ileum biopsies versus stomach biopsies
Colon/Ileum
Biopsy Positive
Colon/Ileum
Biopsy Negative
Total
Stomach biopsy e
Positive
9 14 23 (85.2)
Stomach biopsy e
Negative
1 3 4 (14.8)
Total 10 (37) 17 (63) 27 (100)
p-value ¼ 0.001
(Mc Nemar test)
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Introduction: Graft-versus-host disease (GvHD) is a major
cause of mortality in allogeneic stem cell transplantation
(ASCT). This study assessed the distribution and concordance
of GvHD in upper and lower gastrointestinal (GI) biopsies
and its correlation with CMV infection and extra-intestinal
manifestations of GvHD.
Methods: We performed a review of records from patients
that had undergone ASCT from 2005 to 2013 in our institu-
tion and had GI GvHD diagnosis by histological samples from
upper and/or lower endoscopy. We also evaluate presence of
extra-intestinal manifestations of GvHD at the time of biopsy
and CMV infection on histological and blood samples.
Results: One hundred and eighty nine patients had per-
formed ASCT during this period. Twenty eight patients
(14.8%) had upper and/or lower acute GvHD diagnosis
conﬁrmed by biopsy. Extra-intestinal manifestation of GVHD
was: skin in 19 (67.9%) and liver in 6 (21.4%) patients. Five
(17.9%) had the 3 organ involvement. The GI GvHD staging
was: I in 7 (25%), II in 4 (14.3%), III in 9 (32.1%) and IV in 8
(28.6%) patients.
The frequency and correlation between involvement of
different parts of GI-GVHD are presented in Tables 1, 2 and 3.
Nine (32.1%) had a positive blood sample for CMV and 5
(17.9%) had a histological sample (one in stomach, 3 in colon
and one in rectum). Only one patient had both positive
samples. There is no association between GI-GVHD staging
and CMV infection on blood (p¼0.885) and on biopsy (p¼
0.859).Table 1
Correlation between involvement of different parts of gastrointestinal
tract e rectal biopsy versus colon/ileum biopsies
Colon/Ileum Biopsy
Positive
Colon/Ileum
Biopsy Negative
Total
Rectal biopsy e
Positive
16 7 23 (85.2)
Rectal biopsy e
Negative
2 2 4 (14.8)
Total 18 (66.7) 9 (33.3) 27 (100)
p-value ¼ 0.180
(Mc Nemar test)
Table 2
Correlation between involvement of different parts of gastrointestinal tract
e rectal biopsy versus stomach biopsies
Stomach biopsy e
Positive
Stomach biopsy e
Negative
Total
Rectal biopsy e
Positive
8 2 10 (37)
Rectal biopsy e
Negative
10 7 17 (63)
Total 18 (66.7) 9 (33.3) 27 (100)
p-value ¼ 0.039
(Mc Nemar test)The median follow up was 7.2 (1.8-90.6) month. Overall
survival was 40% in 60 months and patients with stage IV
GVHD had a less survival ( P¼ 0.004).
Conclusion: Because sigmoid tract was the most frequent
site of lower GI-GVHD involvement and only in 7.4% of cases
failed to identify this disease, a retosigmoidoscopymay be an
effective procedure for GI-GVHD diagnosis. However, CMV
infection may be underdiagnosed with this approach.405
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Introduction: Autologous graft versus host disease
(autoGVHD) is a recently recognized, rare transplant
complication with signiﬁcant morbidity and mortality.
Pathogenesis and risk factors for autoGVHD are poorly un-
derstood. We hypothesized that patients with multiple
myeloma might be predisposed to autoGVHD through dis-
regulation of immune response resulting from their treat-
ment with immunomodulatory agents (IMiDs) and
chemotherapeutic mobilization regimens.
Patients and Methods: We identiﬁed 8 patients with
multiple myeloma treated between 2005- 2013 with biopsy-
proven autoGVHD after transplant. We identiﬁed 2 non-
autoGVHD controls per autoGVHD patient matched by the
time of hematopoietic progenitor cell (HPC) collection
(within 15 days). Reference samples from HPC products of
autoGVHD, non-autoGVHD myeloma patients, and 7 healthy
controls were thawed and examined for cell surface marker
expression of CD3, CD4, CD8, CD25, and CD56 and intracel-
lular expression of FoxP3 by multicolor ﬂow cytometry. In-
formation on the following variables was collected: number
of transplants prior to developing autoGVHD, mobilization
regimens, exposure to a proteosome inhibitor, bortezomib,
and IMiDs (thalidomide, lenalidomide and pomalidomide),
and human leukocyte class I antigens (HLA A and B).
Results: Myeloma patients with and without autoGVHD
werewell matched for age (60 5.3 and 62.17.8 years) and
sex (50% and 43.8% male). Regulatory T-cells were decreased,
but not signiﬁcantly, in patients with autoGVHD (1.6  1.4%)
compared to non-autoGVHD patients (2.1  1.7%).There was
no difference in the NK cell population in the 2 groups. CD3+
cell percentage was signiﬁcantly lower in autoGVHD (46.6 
12.4%) than the non-autoGVHD patients (59.1  14.4%, p ¼
0.047). On subset analysis of CD3+ cells, CD8+ cells were
found to be signiﬁcantly lower in patients with autoGVHD
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cells. There was a trend towards higher number of trans-
plants in patients who developed autoGVHD (2.1  0.4%)
compared to those who did not (1.6  0.7%, p¼ 0.072). There
was no difference between these groups with respect to
mobilization regimens, exposure to bortezomib and the
IMiDs. HLA B55 positivity was signiﬁcantly associated with
the development of autoGVHD (p¼0.028).
Conclusion: While there was a trend towards a higher
number of transplants being associated with the develop-
ment of autoGVHD in myeloma patients, no differences were
seen in the use of bortezomib, IMiDs and mobilization regi-
mens. However, lower percentages of CD3+ and CD8+ T-cells
in HPC products were signiﬁcantly associated with
autoGVHD, suggesting that increased immunosuppression
following mobilization may be a predisposing factor for
developing autoGVHD in myeloma patients, particularly in
the setting of HLA B55 positivity.406
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Background: At our center, stage 2-4 GI GVHD accounts for
the majority of diagnoses of severe acute (overall grades III-
IV) GVHD and is associated with high morbidity and mor-
tality. The purpose of this study was to analyze factors that
are associated with development of stage 2-4 GI GVHD in a
large population of adult pts undergoing allo-HCT for he-
matologic malignancy.
Patients and Methods: This analysis includes 376 adult pts
who underwent a ﬁrst allo-HCT at Mayo Clinic Arizona be-
tween 2003 and 2013. All pts received FK-based GVHD pro-
phylaxis, combined with either mycophenolate mofetil
(MMF) or methotrexate (MTX); a subset of pts, mostly those
with unrelated donors, also received rabbit ATG (Thymo-
globulin). The use of MMF vs. MTX was based on physician
discretion and program guidelines. Univariate and multi-
variate statistical analyses were performed to evaluate the
impact of pt- and transplant-speciﬁc factors on the incidence
of stage 2-4 GI GVHD.
Results: The median age was 52 (18-76), and median follow-
up for surviving pts is 22 months. Fifty seven pts (15.2%)
developed stage 2-4 GI GVHD at a median of 43 days (range
10-303) after allo-HCT. In univariate analysis, there was no
difference in incidence of stage 2-4 GI GVHD based on age,
CIBMTR risk status, HCT-CI score, donor type, use of ATG, or
sex match. Conditioning regimens were divided into 3
groups: myeloablative (high dose busulfan- and high-dose
TBI-based), melphalan (Mel)-based (ﬂudarabine/BCNU/Mel,
Flu-Mel, and BEAM), and RIC/NMA (Flu-TBI200, low-dose
busulfan + ﬂudarabine, FCR, etc). Pts who received RIC/NMA
conditioning had signiﬁcantly less stage 2-4 GI GVHD (cu-
mulative incidence [CI] at 6 months 2.9%) compared to pts
who received either myeloablative (CI 9.0%) or Mel-based (CI
15.1%) regimens (P ¼ .017). Pts who received MMF had a
signiﬁcantly higher incidence of stage 2-4 GI GVHD (CI at 6months 17.8%) compared to pts who received MTX (9.1% at 6
months; P¼ .008). In amultivariate Cox proportional hazards
analysis adjusted for the factors listed above, both the use of
MMF (vs. MTX) for GVHD prophylaxis (HR 2.33 [95% CI, 1.04
e 5.4]; P ¼ .04, and type of conditioning regimen (RIC/NMA
vs. myeloablative: HR 0.17 [95% CI .03 - .68]; P¼ .01; RIC/NMA
vs. Mel-based: HR .20 [95% CI, .03 - .70]; P ¼ .009 retained
signiﬁcance for development of stage 2-4 GI GVHD.
Conclusions: These data indicate that use of myeloablative
or Mel-based conditioning regimens, as well as the use of
MMF (vs. MTX) for GVHD prophylaxis (in combination with
FK  ATG) are both associated with signiﬁcantly higher rates
of severe GI acute GVHD. The results suggest caution in the
use of MMF as a secondary agent for routine GVHD prophy-
laxis, and emphasize the increased risk of severe GI GVHD
associated with myeloablative or Mel-based conditioning.407
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Introduction: Acute graft versus host disease (aGVHD) is the
most common and serious complication after allogeneic
hematopoietic stem cell transplantation (allo-HSCT). Inci-
dence goes from 30 to 80%; such wide ranges are determined
by various clinical risk factors. Previous infections before the
allo-HSCT may stimulate an immune response and become
an independent risk factor for inducing aGVHD.
Objectives: Determine whether previous infections in the
recipient of an allo-HSCT is a risk factor for the development
of aGVHD in the service of Hematopoietic Stem Cell Trans-
plantation, National Institute of Pediatrics in the period
January 1998 to December 2011.
Material and Methods: Univariate analysis performed to
determine the frequency of aGVHD for each risk factor,
determining bivariate associations between variables in
estimating relative risk in the associations studied. Chi
square and exact Fisher’s tests were used to determine sta-
tistical signiﬁcance. The signiﬁcant variables in the bivariate
analysis, entered into multivariate analysis (logistic regres-
sion) to determine the contribution of each of the factors for
the presence of disease. Value p 0.05 was statistically
signiﬁcant.
Outcomes: 115 patients underwent allo-HSCT. The different
indications for HSCT were:Malignant hematological diseases
69 cases (60%), Primary immunodeﬁciencies 27 cases
(23.4%), Benign hematologic diseases 12 cases (10.4%),
Inherited metabolic diseases 6 cases (5.2%), and Miscella-
neous 1 case (0.86%).
Twenty seven patients developed aGVHD: factors that
increased the risk for the development of aGVHD were: In-
fections three months prior to transplantation (OR 4.5 p
<0.03), Prior infection with cytomegalovirus in the recipient
(OR 4.6 p<0.03), Peripheral blood supply (OR 11.4 p<000.1),
Peripheral blood greater than bone marrow (OR 16.3 p
<0.001), and Cell dose > 8.3 x106/kg (OR 4.6 p <0.03)
Conclusions: We found that the overall incidence of aGVHD
without taking into consideration the clinical grade was
23.4%. Excel infectious processes three months prior to allo-
HSCT process and prior cytomegalovirus infection as relevant
risk factors.
